BlackRock
ALXO icon

BlackRock’s ALX Oncology ALXO Stock Holding History

BlackRock’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$898K Sell
447,799
-2,631
-0.6% -$5.01K ﹤0.01% 4378
2025
Q4 		$509K Buy
450,430
+2,738
+0.6% +$4.15K ﹤0.01% 4480
2025
Q3 		$819K Sell
447,692
-268,605
-37% -$233K ﹤0.01% 4347
2025
Q2 		$297K Sell
716,297
-1,597,503
-69% -$806K ﹤0.01% 4574
2025
Q1 		$1.44M Sell
2,313,800
-70,447
-3% -$84.6K ﹤0.01% 4088
2024
Q4 		$3.98M Sell
2,384,247
-217,529
-8% -$334K ﹤0.01% 3820
2024
Q3 		$4.74M Sell
2,601,776
-85,843
-3% -$319K ﹤0.01% 3717
2024
Q2 		$16.2M Buy
2,687,619
+466,058
+21% +$5.73M ﹤0.01% 3104
2024
Q1 		$24.8M Sell
2,221,561
-13,532
-0.6% -$190K ﹤0.01% 2866
2023
Q4 		$33.3M Buy
2,235,093
+392,074
+21% +$3.72M ﹤0.01% 2730
2023
Q3 		$8.85M Buy
1,843,019
+54,259
+3% +$294K ﹤0.01% 3407
2023
Q2 		$13.4M Buy
1,788,760
+120,136
+7% +$786K ﹤0.01% 3271
2023
Q1 		$7.54M Sell
1,668,624
-32,462
-2% -$246K ﹤0.01% 3463
2022
Q4 		$19.2M Buy
1,701,086
+30,684
+2% +$345K ﹤0.01% 3058
2022
Q3 		$16M Buy
1,670,402
+8,120
+0.5% +$94.6K ﹤0.01% 3161
2022
Q2 		$13.4M Buy
1,662,282
+306,804
+23% +$3.34M ﹤0.01% 3340
2022
Q1 		$22.9M Buy
1,355,478
+14,907
+1% +$254K ﹤0.01% 3091
2021
Q4 		$28.8M Sell
1,340,571
-26,190
-2% -$1.13M ﹤0.01% 3037
2021
Q3 		$101M Buy
1,366,761
+114,456
+9% +$7.63M ﹤0.01% 2208
2021
Q2 		$68.5M Sell
1,252,305
-266,175
-18% -$15.9M ﹤0.01% 2484
2021
Q1 		$112M Buy
1,518,480
+145,731
+11% +$11.5M ﹤0.01% 2128
2020
Q4 		$118M Buy
1,372,749
+543,735
+66% +$32.7M ﹤0.01% 1978
2020
Q3 		$31.3M Buy
+829,014
New +$32.6M ﹤0.01% 2587

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

BlackRock's ALXO Position: Q1 2026 in Review

BlackRock reduced its ALX Oncology (ALXO) stake by 0.58% in Q1 2026, selling an estimated $5.01K and leaving 447,799 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

BlackRock first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $118M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • BlackRock held 447,799 shares of ALX Oncology worth $898K as of Q1 2026.
  • BlackRock sold 2,631 ALX Oncology shares in Q1 2026, an estimated $5.01K.
  • ALX Oncology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4378 holding.
  • BlackRock first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • BlackRock's ALX Oncology position peaked at $118M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.